Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2021

View Archived Issues

New diphtheria threat as antimicrobial resistance evolves

Fungal culprit in Crohn's disease

Harbour begins phase III study in China of HBM-9036 for moderate to severe dry eye

First patient treated in pivotal phase III program of OPT-302 in wet AMD

Phase III MIRA-2 registration study of Nyxol meets primary endpoint

FDA removes clinical hold for phase I/II study of HST-003

DC-402234 enters phase I clinical development in the U.S.

DSMB recommends phase IIb GALACTIC-1 study of GB-0139 to continue with modifications

AstraZeneca provides update on the safety of its COVID-19 vaccine

Phase I studies of hAd5 T-cell COVID-19 vaccine candidate meet safety requirements

Shanghai Zhimeng Biopharma discovers Toll-like receptor 8 agonists

Polycomb protein EED inhibitors identified at Shanghai Blueray Biopharma

Galapagos describes new ENPP2 inhibitors

NLRP3 inflammasome inhibitors patented by Inflazome

Akeso Therapeutics presents type III NKT cell compositions

MaaT-013 shows safety and efficacy in patients with intestinal acute GvHD

DAPK1 as a potential new target in Alzheimer's disease

In vitro and in vivo evaluation of quinazolinone derivative HoLu-12 for oral squamous cell carcinoma

Promotion of Treg destabilization by CTLA-4 blockade depends on Treg glycolysis and CD28 signaling

Phase Ib/II data presented for itolizumab in patients with severe aGvHD

JP-1366 superior to esomeprazole for treating acid-related diseases

Study indicates islatravir implants provide long-term HIV prophylaxis

Topline phase II data on bintrafusp alfa for second-line treatment of biliary tract cancer

Phase III evaluation starts of Medicago's COVID-19 vaccine candidate with GSK adjuvant

Phase III LUCENT-1 induction study of mirikizumab in ulcerative colitis meets endpoints

Moderna begins phase II/III pediatric trial of COVID-19 vaccine candidate mRNA-1273

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...